Beclazon Eco, aerosol 50 mcg/dose 200 doses

HKS for inhalation use. It has anti-inflammatory and anti-allergic effects.

Inhibits release of inflammatory mediators, increases production of lipomodulin – phospholipase A inhibitor, decreases release of arachidonic acid, inhibits synthesis of prostaglandins. It prevents marginal accumulation of neutrophils by reducing inflammatory exudate formation and lymphokine production, inhibits macrophage migration, which leads to slowdown of infiltration and granulation processes.

It increases the number of active β-adrenoreceptors, neutralizes their desensitization, restores the patient’s response to bronchodilators, allowing us to reduce the frequency of their use.

Beclomethasone decreases the number of mast cells in the bronchial mucosa, reduces swelling of the epithelium and mucus secretion by the bronchial glands. Causes relaxation of the smooth muscles of the bronchi, reduces their hyperresponsiveness and improves the indices of external respiratory function.

Does not have mineralocorticoid activity.

In therapeutic doses, it does not cause side effects typical for systemic GCS.

In intranasal administration, it eliminates edema and hyperemia of the nasal mucosa.

Therapeutic effect usually develops after 5-7 days of course use of beclomethasone.

When used topically or topically, it has anti-allergic and anti-inflammatory effects.

Indications

For inhalation use: treatment of bronchial asthma (including those with insufficient effectiveness of bronchodilators and/or sodium cromoglycate, as well as severe hormone-dependent bronchial asthma in adults and children).

For intranasal use: prevention and treatment of year-round and seasonal allergic rhinitis, including hay fever rhinitis, vasomotor rhinitis.

For external and local use: in combination with antimicrobial agents – infectious and inflammatory diseases of the skin and ear.

Pharmacological effect

GCS for inhalation use. Has anti-inflammatory and anti-allergic effects.

Inhibits the release of inflammatory mediators, increases the production of lipomodulin – an inhibitor of phospholipase A, reduces the release of arachidonic acid, and inhibits the synthesis of prostaglandins. Prevents the marginal accumulation of neutrophils, reducing the formation of inflammatory exudate and the production of lymphokines, inhibits the migration of macrophages, which leads to a slowdown in the processes of infiltration and granulation.

Increases the number of active β-adrenergic receptors, neutralizes their desensitization, restores the patient’s response to bronchodilators, allowing them to be used less often.

Under the influence of beclomethasone, the number of mast cells in the bronchial mucosa decreases, the swelling of the epithelium and the secretion of mucus by the bronchial glands decreases. Causes relaxation of bronchial smooth muscles, reduces their hyperreactivity and improves external respiration function.

Does not have mineralocorticoid activity.

In therapeutic doses it does not cause side effects characteristic of systemic corticosteroids.

When used intranasally, it eliminates swelling and hyperemia of the nasal mucosa.

The therapeutic effect usually develops after 5-7 days of course use of beclomethasone.

When applied externally and locally, it has antiallergic and anti-inflammatory effects.

Special instructions

Beclomethasone is not intended for the relief of acute asthmatic attacks. It should also not be used for severe asthma attacks requiring intensive care. The recommended route of administration for the dosage form used should be strictly followed.

Beclomethasone should be used with extreme caution and under close medical supervision in patients with adrenal insufficiency.

The transfer of patients who constantly take GCS orally to inhaled forms can be done only if their condition is stable.

If there is a possibility of developing paradoxical bronchospasm, bronchodilators (for example, salbutamol) are inhaled 10-15 minutes before the administration of beclomethasone.

With the development of candidiasis of the oral cavity and upper respiratory tract, local antifungal therapy is indicated without stopping treatment with beclomethasone. Infectious and inflammatory diseases of the nasal cavity and paranasal sinuses, if appropriate therapy is prescribed, are not a contraindication for treatment with beclomethasone.

Preparations for inhalation containing 250 mcg of beclomethasone in 1 dose are not intended for children under 12 years of age.

Active ingredient

Beclomethasone

Composition

1 dose of aerosol contains:

Active ingredients
Beclomethasone dipropionate 50 mcg.
Excipients

Ethanol, hydrofluoroalkane (HFA-134a).

Pregnancy

Contraindicated in the first trimester of pregnancy.

Use in the second and third trimesters of pregnancy is possible only when the expected benefit to the mother outweighs the potential risk to the fetus. Infants whose mothers received beclomethasone during pregnancy should be closely monitored for adrenal insufficiency.

If it is necessary to use it during lactation, the issue of stopping breastfeeding should be decided.

Contraindications

Hypersensitivity to the components of the drug.

With caution:

-glaucoma;

-systemic infections (bacterial, viral, fungal, parasitic);

-osteoporosis;

– pulmonary tuberculosis;

– liver tyrrhosis;

-hypothyroidism;

-pregnancy;

– lactation period.

Side Effects

From the respiratory system: hoarseness, feeling of irritation in the throat, sneezing; rarely – cough; in isolated cases – eosinophilic pneumonia, paradoxical bronchospasm, with intranasal use – perforation of the nasal septum. Candidiasis of the oral cavity and upper respiratory tract is possible, especially with long-term use, which resolves with local antifungal therapy without stopping treatment.

Allergic reactions: rash, urticaria, itching, erythema and swelling of the eyes, face, lips and larynx.

Effects caused by systemic action: decreased function of the adrenal cortex, osteoporosis, cataracts, glaucoma, growth retardation in children.

Interaction

With simultaneous use of beclomethasone with other corticosteroids for systemic or intranasal use, increased suppression of adrenal cortex function is possible. Previous inhaled use of beta-agonists may increase the clinical effectiveness of beclomethasone.

Overdose

Acute overdose

Symptoms: temporary decrease in function of the adrenal cortex.
Treatment: No emergency treatment is required, as adrenal function is restored within a few days, as evidenced by plasma cortisol levels.

Chronic overdose

Symptoms: persistent suppression of adrenal function may occur.
Treatment: it is recommended to monitor the reserve function of the adrenal cortex.

In case of overdose, treatment with beclomethasone dipropionate can be continued in doses sufficient to maintain the therapeutic effect.

Storage conditions

Store in a place protected from light at a temperature not exceeding 30 °C (do not freeze or heat).
Keep out of the reach of children.

Shelf life

2 years.

Manufacturer

Norton (Waterford) Limited/IVEX Pharmaceuticals I, Ireland